U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT06860971) titled 'A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma' on Feb. 24.
Brief Summary: This study aims to demonstrate that, in subjects with locally advanced or metastatic iodine - refractory differentiated thyroid cancer who have failed previous VEGFR - targeted therapy, AL2846 can significantly prolong progression - free survival (PFS) compared with placebo.
Study Start Date: March, 2025
Study Type: INTERVENTIONAL
Condition:
Thyroid Cancer
Intervention:
DRUG: AL2846 Capsules
AL2846 Capsule is a multi - target tyrosine kinase inhibitor, which has significant ...